Fresenius Medical Care Corporation (NYSE:FMS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Monday, July 31st.
Other analysts have also recently issued reports about the company. Zacks Investment Research raised Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Tuesday, April 25th. Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada reissued a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a research report on Wednesday, July 5th. DZ Bank AG reissued a “neutral” rating on shares of Fresenius Medical Care Corporation in a research report on Monday, May 29th. Finally, UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $48.67.
Shares of Fresenius Medical Care Corporation (FMS) traded down 0.06% during midday trading on Monday, hitting $46.44. 84,457 shares of the stock were exchanged. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The firm’s 50 day moving average price is $47.37 and its 200-day moving average price is $44.93. The stock has a market cap of $28.50 billion, a P/E ratio of 20.28 and a beta of 0.47.
Fresenius Medical Care Corporation (NYSE:FMS) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The company had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the firm posted $0.96 earnings per share. The company’s revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts expect that Fresenius Medical Care Corporation will post $2.33 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Harding Loevner LP increased its position in Fresenius Medical Care Corporation by 7.1% in the first quarter. Harding Loevner LP now owns 3,528,960 shares of the company’s stock valued at $148,675,000 after buying an additional 233,347 shares during the period. Cambiar Investors LLC increased its position in shares of Fresenius Medical Care Corporation by 8.1% in the first quarter. Cambiar Investors LLC now owns 2,516,416 shares of the company’s stock worth $106,017,000 after buying an additional 188,019 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Fresenius Medical Care Corporation during the first quarter worth approximately $7,887,000. Renaissance Technologies LLC bought a new position in shares of Fresenius Medical Care Corporation during the first quarter worth approximately $7,141,000. Finally, Bank of America Corp DE increased its position in shares of Fresenius Medical Care Corporation by 12.1% in the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock worth $62,917,000 after buying an additional 161,262 shares during the last quarter. 2.81% of the stock is currently owned by institutional investors.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
